Modified immune effector cells with increased resistance to cell death

Through genetic engineering technology, TRAIL receptor knockout and TRAIL ligand expression variants, as well as chimeric antigen receptor methods, the problem of TRAIL-induced cell death and insufficient cytotoxicity in immune cell therapy has been solved, and further achieved Efficient cancer cell killing and safety.

CN113677791BInactive Publication Date: 2024-12-03ONK THERAPEUTICS LTD
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
CN202080022826.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-02-06
Filing Date
2020-03-20
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing immune cell therapy has problems with TRAIL-induced cell death and insufficient cytotoxicity in anti-cancer, especially when the mechanisms against TRAIL deception receptors are difficult to overcome and the risk of self-killing is high.

Method used

Enhance the cytotoxicity of immune effector cells and resist TRAIL-induced cells by genetically engineering knockout or knockdown of TRAIL receptors, expressing TRAIL ligand variants and chimeric antigen receptors (CARs), and reducing inhibitory receptor function, as well as reducing inhibitory receptor function. die.

Benefits of technology

It significantly improves the resistance and cytotoxicity of immune effector cells to TRAIL-induced cell death, enhances the killing ability of cancer cells, reduces the risk of self-killing, and provides a safer and more effective cancer treatment method.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113677791B_ABST
    Figure CN113677791B_ABST
Patent Text Reader

Abstract

Immune effector cells and immune effector cell lines are modified to increase resistance to TRAIL-induced cell death by knocking out the TRAIL receptor or by linking the TRAIL receptor to an immune effector cell co-stimulatory domain, or both.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] introduction

[0002] The present invention relates to modifying immune effector cells and immune effector cell lines to prepare useful derivatives thereof. In addition, the present invention relates to methods for preparing modified immune effector cells and cell lines, compositions containing the cells and cell lines, and uses of the cells and compositions containing the cells in cancer treatment. Background Art

[0003] Normally, immune cells require target cells to present antigens via the major histocompatibility complex (MHC) before they can trigger an immune response that leads to target cell death. This allows cancer cells that do not present MHC class I to evade most immune responses.

[0004] However, in the absence of MHC class I expression, NK cells are able to recognize cancer cells. Therefore, they play a key role in the body's defense against cancer.

[0005] On the other hand, in certain cases, cancer cells exhibit the ability to inhibit the cytotoxic activity of immune effector cells such as NK cells and T cells by expressing ligands that bind to inhibitory receptors on the cell membrane. Resistance to cancer may involve a balance between these and other factors.

[0006] In this article, cytotoxicity refers to immune effector cells such as NK cells and T cells, by, for example, releasing cytolytic proteins, or by binding to receptors on cancer cell membranes and inducing apoptosis (whether directly or indirectly) of the cancer cells and inducing the ability of cancer cell death. Cytotoxicity is not only affected by the signal of inducing cytolytic protein release, but also by the signal of inhibiting cytolytic protein release. As mentioned above, the increase of cytotoxicity will therefore lead to more effectively killing cancer cells, and the chance of cancer cells suppressing the cytotoxic activity of immune effector cells is smaller.

[0007] Removal of inhibitory receptor function on NK cells by genetic modification has been suggested as a method for increasing NK cell cytotoxicity against cancer cells that lack MHC class I expression but are able to inhibit NK cytotoxicity (Bodduluru et al., 2012). NKG2A has been identified as an inhibitory receptor worth silencing in these cases because certain cancer cells are known to express HLA-E, which binds to NKG2A and inhibits NK cell cytotoxicity in the absence of MHC class I expression (Shook et al., 2011; WO 2006 / 023148) (Campana D. et al., 2019).

[0008] Another approach to downregulate NKG2A expression has been shown in NK-92 cells, where transfection of the gene encoding IL-15 was shown to be associated with a reduction in NKG2A expression (Zhang et al., 2004). However, although an increase in NK cell cytotoxicity was observed, this increase was most likely a result of a concomitant increase in expression of the activating receptor NKG2D. This view is supported by the observation that blockade of the NKG2A receptor on NK-92 cells was not associated with increased cytotoxicity against multiple myeloma cells (Heidenreich et al., 2012). However, it is important to note that the NK-92 cell line is a highly cytotoxic cell line with very low expression of inhibitory receptors. Therefore, any increase in cytotoxicity associated with a reduction in NKG2A expression would likely be too negligible to be detected.

[0009] Similar studies have been conducted in mice. For example, mice express a receptor on NK cells called Ly49 that is similar to human inhibitory KIR receptors. It has been shown that by blocking the Ly49 receptor with antibody fragments, NK cells have more potent cytotoxicity and are able to kill murine leukemia cells in vitro and in vivo (Koh et al., 2001).

[0010] However, as a result of the reduced inhibitory receptor function, "normal" cells in the body also become more vulnerable to attack by the modified NK cells, because the modified NK cells become less able to distinguish between "normal" cells and cancer cells. This side effect is a significant disadvantage of reducing the function of "classic" inhibitory receptors.

[0011] Another way that NK cells are known to kill cancer cells is to express TRAIL on their surface. TRAIL ligands can bind to TRAIL receptors on cancer cells and induce apoptosis of the cancer cells. A speculative approach describes overexpressing membrane-bound TRAIL ligands on NK cells in order to exploit this anti-cancer mechanism (EP1621550). In addition, it has been reported that IL-12 can upregulate TRAIL expression on NK cells (Smyth et al., 2001).

[0012] However, cancer cells have developed evasive and protective mechanisms to deal with TRAIL-expressing NK cells. Decoy TRAIL receptors are often expressed on the membrane of cancer cells, and TRAIL binding to these decoy receptors (such as DcR1 and DcR2) cannot induce apoptosis; a method to overcome this mechanism has not yet been found.

[0013] Another problem with using TRAIL-expressing NK cells to target cancer cells is that some NK cells themselves express TRAIL receptors. Therefore, in some cases, TRAIL expression on NK cells may lead to self-killing (fratricide).

[0014] Acute myeloid leukemia (AML) is a hematopoietic malignancy that involves precursor cells committed to myeloid development and accounts for a large proportion of acute leukemias in adults (90%) and children (15-20%) (Hurwitz, Mounce et al., 1995; Lowenberg, Downing et al., 1999). Although 80% of patients achieve remission with standard chemotherapy (Hurwitz, Mounce et al., 1995; Ribeiro, Razzouk et al., 2005), survival remains unsatisfactory due to high rates of relapse with minimal residual disease (MRD). The 5-year survival rate is age-dependent; it is 60% in children (Rubnitz, 2012), 40% in adults under 65 years of age (Lowenberg, Downing et al., 1999), and 10% in adults over 65 years of age (Ferrara and Schiffer, 2013). These outcomes can be improved if patients have a suitable hematopoietic cell donor, but many do not, highlighting the need for an alternative treatment approach.

[0015] Natural killer (NK) cells are cytotoxic lymphocytes with unique phenotypes and effector functions that are different from, for example, natural killer T (NK-T) cells. For example, although NK-T cells express both CD3 and T cell antigen receptors (TCRs), NK cells do not express them. It is generally found that NK cells express markers CD16 and CD56, wherein CD16 acts as an Fc receptor and mediates antibody-dependent cell-mediated cytotoxicity (ADCC), which will be discussed below. In this regard, KHYG-1 is a significant exception. Although NK cells have natural cytotoxicity, NK cell lines with enhanced cytotoxicity have been developed. NK-92 and KHYG-1 represent two NK cell lines that have been widely studied and have shown promise in cancer treatment (Swift et al., 2011; Swift et al., 2012).

[0016] Adoptive cellular immunotherapy for cancer treatment typically involves administering natural and modified T cells to patients. T cells can be modified in various ways, such as genetic modification, to express receptors and / or ligands that specifically bind to certain target cancer cells. T cells are transfected with high-affinity T cell receptors (TCRs) and chimeric antigen receptors (CARs) that are specific for cancer cell antigens, which can cause highly reactive cancer-specific T cell responses. A major limitation of this immunotherapy approach is that T cells must be obtained from the patient for autologous in vitro expansion, or MHC-matched T cells must be used to avoid immune eradication immediately after the cells are transferred to the patient, or in some cases, the onset of graft-versus-host disease (GVHD). In addition, successfully transferred T cells usually survive in the circulation for a long time, making it difficult to control the persistent side effects of treatment.

[0017] In the setting of haploidentical bone marrow transplantation, when there is a KIR inhibitory receptor-ligand mismatch, the graft-versus-leukemia effect is thought to be mediated by NK cells, which can improve survival in the treatment of AML (Ruggeri, Capanni et al., 2002; Ruggeri, Mancusi et al., 2005). In addition, in patients who receive T-depleted hematopoietic cell transplantation (HCT) in AML, rapid NK recovery is associated with better outcomes and a stronger graft-versus-leukemia (GVL) effect (Savani, Mielke et al., 2007). Other trials have used ex vivo expanded haploid NK cells to treat AML in adults (Miller, Soignier et al., 2005) and children (Rubnitz, Inaba et al., 2010).

[0018] Several permanent NK cell lines have been established, the most notable of which is NK-92, which was derived from a patient with non-Hodgkin's lymphoma that expresses typical NK cell markers, except for CD16 (Fcγ receptor III). NK-92 has undergone extensive preclinical testing and has shown superior lytic capacity against a variety of tumors compared to activated NK cells and lymphokine-activated killer (LAK) cells (Gong, Maki et al., 1994). The cytotoxicity of NK-92 cells against primary AML has been established (Yan, Steinherz et al., 1998).

[0019] Another NK cell line, KHYG-1, has been identified as a potential contender for clinical application (Suck et al., 2005), but has reduced cytotoxicity and has therefore received less attention than NK-92. KHYG-1 cells are known to be pre-activated. Unlike endogenous NK cells, KHYG-1 cells are always in a polarized state, increasing their cytotoxicity and making them more responsive to external stimuli. The baseline cytotoxicity of NK-92 cells is higher than that of KHYG-1 cells.

[0020] It is therefore clear that current adoptive immunotherapy protocols are subject to variability in the number and quality of donor effector cells, variables that could be eliminated if potent cell lines were available to provide more standardized therapy.

[0021] NK cell cytotoxicity has been extensively studied using mouse models. One example is the finding that perforin and granzyme B mRNA are constitutively transcribed in mouse NK cells, but minimal levels of protein are detected prior to stimulation or activation of NK cells (Fehniger et al., 2007). Although this study and others using mouse NK cells are noteworthy, they cannot be taken as definitive evidence of human NK cell cytotoxicity. In contrast to the above examples, human NK cells express high levels of perforin and granzyme B proteins prior to stimulation (Leong et al., 2011). As a result, when mouse or human NK cells are freshly isolated in culture, mouse NK cells have weak cytolytic activity, while human NK cells exhibit strong cytolytic capacity.

[0022] Mouse and human NK cells also differ greatly in terms of expression markers, signaling cascades, and tissue distribution. For example, CD56 is used as a marker for human NK cells, while mouse NK cells do not express this marker at all. In addition, a well-established mechanism for regulating NK cell cytotoxicity is through binding to ligands of NK activation and inhibitory receptors. The two most prominent human NK activation receptors known are NKp30 and NKp44, neither of which is expressed on mouse NK cells. Regarding NK inhibitory receptors, while human NK cells express KIRs that recognize MHC class I and inhibit cytotoxic activity, mouse NK cells do not express KIRs at all, but instead express Ly49s (Trowsdale et al., 2001). In summary, although mouse NK cells achieve the same functions as human NK cells in their natural physiological environment, the mechanisms by which this is achieved differ significantly between species.

[0023] Therefore, there is a need for alternative and preferably improved immune effector cells and cell lines, for example with more potent cytotoxic characteristics.

[0024] An object of the present invention is to provide immune effector cells and immune effector cell lines that are not susceptible to TRAIL-induced cell death and / or have a stronger cytotoxic phenotype. Another object is to provide a method for preparing modified immune effector cells and cell lines, a composition containing the cells or cell lines, and the use of the composition in treating cancer. More specific embodiments are intended to provide treatment for identified cancers, such as blood cancers, such as leukemias; and solid tumors. Specific embodiments are intended to combine two or more modifications of immune effector cells and cell lines to further enhance the cytotoxicity of modified cells. Summary of the invention

[0025] Provided herein are modified immune effector cells and cell lines that are resistant to TRAIL-induced cell death and, optionally, but preferably, have a more cytotoxic phenotype. Further, methods for preparing the cells and cell lines are provided. Also provided are compositions of the modified immune effector cells and cell lines, and uses of the cells and compositions for treating cancer.

[0026] Preferably, the immune effector cells / cell lines are selected from NK cells and T cells.

[0027] The present invention provides methods for modifying immune effector cells, using, for example, genetic engineering to knock out and / or knock down genes encoding TRAIL receptors, inhibitory receptors and / or checkpoint inhibitory receptors, express genes encoding modified TRAIL receptors, TRAIL ligands and variants, and / or express genes encoding chimeric antigen receptors (CAR) and / or Fc receptors.

[0028] Additionally, compositions of the invention include immune effector cells and immune effector cell lines in which two or more modifications are provided, wherein the multiple modifications further enhance the cytotoxic activity of the cells and cell lines.

[0029] The present invention provides immune effector cells or immune effector cell lines that have been modified to have increased resistance to TRAIL-induced cell death. The cells themselves are resistant to TRAIL-induced cell death. Preferably, the cells have been modified (e.g., genetically modified) to have reduced function of one or more TRAIL receptors.

[0030] According to the present invention, there is further provided a method for treating cancers such as blood cancers and solid tumors using modified immune effector cell lines, such as NK-92 cells and derivatives thereof, wherein the modified immune effector cell lines are optionally further engineered to lack expression of checkpoint inhibitory receptors, express TRAIL ligand variants and / or express CAR and / or Fc receptors.

[0031] Diseases that are particularly treatable according to the invention include cancer, blood cancer, leukemia and in particular acute myeloid leukemia. In particular, human tumors and cancers can be treated. References to tumors herein include references to neoplasms.

[0032] Thus, the present invention provides immune effector cells or cell lines modified to resist TRAIL-induced cell death. Thus, the cells may be less susceptible to TRAIL-induced cell death or self-killing.

[0033] The immune effector cells are preferably lymphocytes.

[0034] In a preferred embodiment, the lymphocytes are NK cells. The NK cells are preferably primary NK cells, KHYG-1 cells or NK-92 cells.

[0035] In other preferred embodiments, the lymphocytes are T cells. The T cells are preferably primary T cells or Jurkat cells.

[0036] As described in detail below, immune effector cells have been genetically modified so as to increase their resistance to TRAIL-induced cell death, and optionally to increase their cytotoxic activity against cancer cells.

[0037] The immune effector cells and cell lines of the present invention will be collectively referred to as immune effector cells (unless the context requires otherwise). Similarly, T cells shall include T cell lines, and NK cells shall include NK cell lines (unless the context requires otherwise).

[0038] In a series of preferred embodiments, immune effector cells have been modified to have the function of one or more TRAIL receptors reduced. Optionally, this is achieved by gene knockout or knocking down (e.g., using siRNA) or limiting the expression of TRAIL receptors in the endoplasmic reticulum of cells. Advantageously, modified cells are resistant or have higher resistance to the cell death achieved by the TRAIL signal transduction pathway.

[0039] Preferably, the DR4 and / or DR5 function on the cells of the present invention is reduced. It is particularly preferred that the DR4 and / or DR5 gene is knocked out. If multiple gene copies are present, preferably all are knocked out.

[0040] Other methods of reducing the sensitivity of cells to TRAIL-induced cell death can be used. Alternatively, TRAIL-induced cell death is reduced by overexpressing c-FLIP in immune effector cells and / or by knocking down the expression of caspase 8. Therefore, in the NK cells and T cells of the present invention, c-FLIP may be overexpressed. Therefore, similarly, in the NK cells and T cells of the present invention, caspase 8 expression is reduced or knocked down or knocked out.

[0041] Immune effector cells can be modified in a way that both reduces TRAIL-induced cell death and provides the cells with a more cytotoxic phenotype. Preferably, the same modification can achieve both advantages.

[0042] Relative to wild-type immune effector cells, the resistance of immune effector cells to TRAIL-induced cell death is preferably increased by at least 5%, more preferably at least 10%, more preferably at least 25%, and most preferably at least 50%. Resistance to cell death can be measured in a variety of ways known to those skilled in the art, such as by performing cell viability assay. Preferably, flow cytometry propidium iodide cell viability assay is used to measure the increased resistance to cell death. In an example, a test is performed to identify immune effector cell populations (cell populations) modified according to the present invention to show an increase in resistance to TRAIL-induced cell death of at least 10%, wherein soluble TRAIL is incubated with (1) modified cells and (2) wild-type cells, and then after each cell population is stained with propidium iodide, it is found that the cell viability of the modified cell population is at least 10% higher than the wild-type population.

[0043] Preferably, immune effector cells are modified to express TRAIL receptors connected to costimulatory domains. The cell can express TRAIL receptors connected to one or more costimulatory domains. Preferably, TRAIL receptors are selected from DR4 and DR5. Preferably, costimulatory domains are selected from one or more of 4-1BB, CD28, 2B4, DAP-10, DAP-12, CD278 (ICOS) and OX40. More preferably, the costimulatory domain is 4-1BB connected to CD3zeta.

[0044] Costimulatory domain is a protein domain, which provides signals in addition to the signals sent by antigen receptors (such as DR4 or DR5), and can help induce the complete activation of lymphocytes (such as NK cells). The complete activation of immune effector cells causes cytokine production, sustained proliferation, anti-apoptotic intracellular signaling and / or enhances the sensitivity of further stimulation by antigen receptors. In general, this provides a more cytotoxic phenotype for immune effector cells. Therefore, the combination of ligand and the receptor connected to the costimulatory domain activates this cell stimulation result of ligand binding.

[0045] By comparing with the cytotoxicity of wild-type cells without such modification, the increase or enhancement of cytotoxicity caused by the modification of immune effector cells is defined. Wild-type cells are defined as cells identical to the cell type comprising the modification but not containing the modification itself. For example, the invention provides NK-92 cells modified to express DR5 connected to costimulatory domain CD28; relative to wild-type NK-92 cells (i.e., NK-92 cells that are not modified to express DR5 connected to CD28), these NK cells are modified to show increased cytotoxicity to cancer cells.

[0046] KHYG-1 cells usually express low levels of DR4 and DR5 when resting. However, when the cells are activated or affected by / exposed to exogenous factors, the expression of DR4 and / or DR5 may be upregulated. Therefore, according to the present invention, KHYG-1 cells may also be appropriately modified.

[0047] Relative to wild-type immune effector cells, the immune effector cells of the present invention are preferably increased by at least 10% to the cytotoxicity of target (e.g., cancer) cells, more preferably at least 20%, more preferably at least 50%, and most preferably at least 100%. During incubation with immune effector cells, when target cell death is determined using known methods, cytotoxicity is easily measured. Preferably, the increased cytotoxicity is measured using a flow cytometry propidium iodide cell viability assay. In one example, a test is performed to identify an immune effector cell group modified according to the present invention to show an increase in cytotoxicity of at least 10% to cancer cells, wherein the target cancer cells are incubated with (1) modified cells of the present invention or (2) wild-type (i.e., unmodified) immune effector cells, and then after staining each cancer cell group, it is found that the cell viability of those cancer cells incubated with wild-type immune effector cells is at least 10% higher than that of the cancer cells incubated with the modified immune effector cell group.

[0048] Advantageously, the TRAIL receptor that is connected to one or more costimulatory domains competes with the existing TRAIL receptor on the immune effector cell surface of the present invention, thereby limits the combination of TRAIL and the TRAIL receptor of these induction death. In addition, the immune effector cell expressing the TRAIL receptor connected with the costimulatory domain produces an activation signal when combined with TRAIL, which increases the cytotoxic activity of the immune effector cell. When using modified immune effector cell therapy cancer, this may be a particularly advantageous feature.

[0049] In all series of embodiments of the present invention, immune effector cells with reduced or lacking checkpoint inhibitory receptor function can be provided. Such immune effector cells of the present invention preferably have one or more knocked-out checkpoint inhibitory receptor genes. Preferably, these receptors are specific checkpoint inhibitory receptors. Still preferably, these checkpoint inhibitory receptors are one or more or all of CD96 (TACTILE), CD152 (CTLA4), CD223 (LAG-3), CD279 (PD-1), CD328 (SIGLEC7), SIGLEC9, TIGIT and TIM-3.

[0050] In other embodiments, immune effector cells are provided in which one or more inhibitory receptor signaling pathways are knocked out or exhibit reduced function - again resulting in reduced or absent inhibitory receptor function. For example, signaling pathways mediated by SHP-1, SHP-2 and / or SHIP are knocked out by genetic modification of the cells.

[0051] The resulting immune effector cells exhibit improved cytotoxicity and therefore have greater utility in cancer therapy, particularly blood cancer therapy, particularly in the treatment of leukemia and / or multiple myeloma.

[0052] Genetic modification may occur before the cells differentiate into mature immune effector cells. For example, pluripotent stem cells (e.g., iPSCs) may be genetically modified to lose the ability to express one or more checkpoint inhibitory receptors. The modified iPSCs are then differentiated to prepare genetically modified immune effector cells with increased cytotoxicity.

[0053] Since checkpoint inhibitory receptors are expressed after activation of immune effector cells, it is preferred to reduce the function of checkpoint inhibitory receptors compared to other inhibitory receptors. Normal or "typical" inhibitory receptors, such as most KIR families, NKG2A and LIR-2, bind to MHC class I and are therefore primarily involved in reducing self-targeting problems. Therefore, preferably, checkpoint inhibitory receptors are knocked out. According to the present invention, the reduction or absence of the function of these receptors prevents cancer cells from inhibiting immune effector functions (which may occur if the receptors are fully functional). Therefore, a key advantage of these embodiments of the present invention is that immune effector cells are less sensitive to cancer cells inhibiting their cytotoxic activity; therefore, they can be used in cancer treatment.

[0054] As used herein, mentioning inhibitory receptors generally refers to receptors expressed on the plasma membrane of immune effector cells, such as NK cells, thereby binding to its complementary ligand to produce intracellular signals responsible for reducing the cytotoxicity of the immune effector cells. These inhibitory receptors are expressed during the "resting" and "activated" states of immune effector cells, and are generally related to providing the immune system with a "self-tolerance" mechanism that inhibits cytotoxic responses to body cells and tissues. An example is the inhibitory receptor family "KIR", which is expressed on NK cells and recognizes MHC class I expressed on healthy cells of the body.

[0055] Also as used herein, checkpoint inhibitory receptors are generally considered to be a subset of the inhibitory receptors generally mentioned above. However, unlike other inhibitory receptors, checkpoint inhibitory receptors are expressed at higher levels during the sustained activation and cytotoxicity of immune effector cells, such as NK cells. This phenomenon is useful for inhibiting chronic cytotoxicity at sites of inflammation, for example. Examples include checkpoint inhibitory receptors PD-1, CTLA-4, and CD96, all of which are expressed on NK cells.

[0056] The immune effector cells of the present invention may also lack genes encoding checkpoint inhibitory receptors selected from CD96 (TACTILE), CD152 (CTLA4), CD223 (LAG-3), CD279 (PD-1), CD328 (SIGLEC7), SIGLEC9, TIGIT and TIM-3.

[0057] Immune effector cells lacking a gene may refer to a complete or partial deletion, mutation, or other condition resulting in substantially no functional gene product being expressed. The inventors have previously demonstrated the cytotoxic effect of knocking down the expression of checkpoint inhibitory receptors in KHYG-1 cells using siRNA. KHYG-1 cells with CD96 knockdown (KD) exhibit enhanced cytotoxicity to leukemia cells at various ratios of effector: target (E:T). In embodiments, immune effector cells lack genes encoding two or more inhibitory receptors.

[0058] More specific embodiments include immune effector cells lacking genes encoding checkpoint inhibitory receptors selected from CD96 (TACTILE), CD152 (CTLA4), and CD279 (PD-1).

[0059] In a further preferred embodiment, the immune effector cell is a derivative of the following cells: primary T cells, NK cells or NK-92 NK cells. The NK cells may also be a derivative of KHYG-1 cells.

[0060] Preferably, the immune effector cells of the invention further express mutant (variant) TRAIL ligands. Thus, the cytotoxicity-enhancing modification of immune effector cells also includes increased expression of both TRAIL ligands and / or mutant TRAIL ligand variants.

[0061] The generated immune effector cells show increased binding to the TRAIL receptor and, therefore, increased cytotoxicity towards cancer, especially blood cancers, especially leukemias.However, due to the modifications described above and below, the immune effector cells of the invention are less sensitive to TRAIL-induced cell death.

[0062] Compared to the binding of wild-type TRAIL to decoy receptors, the mutant / variant preferably has a lower affinity (or virtually no affinity) for the "decoy" receptor. Such decoy receptors represent a class of TRAIL receptors that bind to TRAIL ligands but do not have the ability to trigger cell death and, in some cases, act to antagonize the death signaling pathway. Mutant / variant TRAIL ligands may be prepared according to WO2009 / 077857.

[0063] Mutants / variants may have increased affinity for TRAIL receptors, such as DR4 and DR5, respectively. It is generally known that the K of wild-type TRAIL is D For DR4>2nM, for DR5>5nM, and for the decoy receptor DcR1>20nM (WO 2009 / 077857; measured by surface plasmon resonance), or about 50 to 100nM for DR4, about 1 to 10nM for DR5, and about 175 to 225nM for DcR1 (Truneh, A et al., 2000; measured by isothermal titration calorimetry and ELISA). Therefore, according to the defined analysis, the increase in affinity for DR4 is preferably defined as K D <2 nM or <50 nM, and the increased affinity for DR5 is preferably defined as K D <5nM or <1nM. The reduced affinity for the decoy receptor DcR1 is preferably defined as K D >50nM or >225nM. In any case, the increase or decrease in affinity exhibited by the TRAIL variant / mutant is relative to the baseline affinity exhibited by wild-type TRAIL. Compared to the affinity exhibited by wild-type TRAIL, the affinity is preferably increased by at least 10%, at least 25%, at least 50%, more preferably at least 100%.

[0064] The TRAIL variant preferably has an increased affinity for one or both of DR4 and DR5 compared to its affinity for wild-type TRAIL. Preferably, the affinity for DR4 and / or DR5 is at least 1.5-fold, 2-fold, 5-fold, 10-fold, 100-fold, or even 1000-fold greater than that for wild-type TRAIL.

[0065] In certain cases, the affinity of the TRAIL variant for DR5 may be increased compared to its affinity for DR4, DcR1 and DcR2. Preferably, the affinity of the TRAIL variant for DR5 is at least 1.5 times, 2 times, 5 times, 10 times, 100 times or even 1000 times greater than the affinity for one or more of DR4, DcR1 and DcR2. More preferably, the affinity of the TRAIL variant for DR5 is at least 1.5 times, 2 times, 5 times, 10 times, 100 times or even 1000 times greater than the affinity for at least two (preferably all) of DR4, DcR1 and DcR2.

[0066] Further specific embodiments include immune effector cells expressing TRAIL ligands of mutations, the TRAIL ligands of mutations have reduced or no affinity for TRAIL decoy receptors. Preferably, the immune effector cells are derivatives of NK-92. Further specific embodiments include immune effector cells expressing TRAIL ligands of mutations, the TRAIL ligands of mutations have reduced or no affinity for TRAIL decoy receptors, and increased affinity for DR4 and / or DR5.

[0067] A key advantage of these embodiments of the present invention is immune effector cells that have multiple modifications and greater potential in killing cancer cells compared to wild-type cells.

[0068] In certain embodiments, the TRAIL variant comprises at least one amino acid substitution at a position selected from 131, 149, 159, 160, 189, 191, 193, 195, 199, 200, 201, 203, 204, 212, 213, 214, 215, 218, 240, 251, 261, 264, 266, 267, 269 and 270.

[0069] In certain embodiments, the TRAIL variant comprises at least one substitution selected from the group consisting of G131R, G131K, R149I, R149M, R149N, R149K, S159R, G160E, Y189A, Y189Q, R191K, Q193H, Q193K, Q193S, Q193R, E195R, N199V, N199R, N199H, T200H, K201R, K201H, D203A, K204E, K204D, K204Y, K212R, Y213W, T214R, S215D, S215E, S215H, S215K, S215D, D218H, D218A, Y240A, K251D, K251E, K251Q, T261L, H264R, I266L, D267Q, D269A, D269H, and H270D.

[0070] In certain embodiments, the TRAIL variant comprises at least two substitutions selected from the group consisting of G131R, G131K, R149I, R149M, R149N, R149K, S159R, G160E, Y189A, Y189Q, R191K, Q193H, Q193K, Q193S, Q193R, E195R, N199V, N199R, N199H, T200H, K201R, K201H, D203A, K204E, K204D, K204Y, K212R, Y213W, T214R, S215D, S215E, S215H, S215K, S215D, D218H, D218A, Y240A, K251D, K251E, K251Q, T261L, H264R, I266L, D267Q, D269A, D269H, and H270D.

[0071] In certain embodiments, the TRAIL variant comprises at least three substitutions selected from the group consisting of G131R, G131K, R149I, R149M, R149N, R149K, S159R, G160E, Y189A, Y189Q, R191K, Q193H, Q193K, Q193S, Q193R, E195R, N199V, N199R, N199H, T200H, K201R, K201H, D203A, K204E, K204D, K204Y, K212R, Y213W, T214R, S215D, S215E, S215H, S215K, S215D, D218H, D218A, Y240A, K251D, K251E, K251Q, T261L, H264R, I266L, D267Q, D269A, D269H, and H270D.

[0072] In certain embodiments, the amino acid substitutions of the TRAIL variant are selected from the group consisting of: G131R, G131K, R149I, R149M, R149N, R149K, S159R, G160E, Y189A, Y189Q, R191K, Q193H, Q193K, Q193S, Q193R, E195R, N199V, N199R, N199H, T200H, K201R, K201H, D203A , K204E, K204D, K204Y, K212R, Y213W, T214R, S215D, S215E, S215H, S215K, S215D, D218H, D218A, Y2 40A, K251D, K251E, K251Q, T261L, H264R, I266L, D267Q, D269A, D269H, H270D, T214R / E195R, T214R / D269H、Y189A / Q193S / N199V / K201R / Y213W / S215D、Y213W / S215D、N199R / K201H、N199H / K201R、G1 31R / N199R / K201H, G131R / N199R / K201H / R149I / S159R / S215D, G131R / R149I / S159R / S215D, G131R / N199R / K201H / R149I / S159R / S215D, G131R / D218H, Y189Q / R191K / Q193R / H264R / I266L / D267Q, T261L / G160E, T261L / H270D, T261L / G160E / H270D and T261L / G160E / H270D / T200H (multiple amino acid substitutions are indicated by “ / ”).

[0073] In certain embodiments, amino acid substitutions of TRAIL variants are selected based on variants having increased affinity for DR5; such substitutions may be selected from: D269H, E195R, T214R, D269H / E195R, T214R / E195R, T214R / D269H, N199V, Y189A / Q193S / N199V / K201R / Y213W / S215D, Y213W / S215D, D269A and Y240A.

[0074] In certain embodiments, the amino acid substitutions of the TRAIL variants are selected based on the variants having increased affinity for DR4; such substitutions may be selected from G131R, G131K, R149I, R149M, R149N, R149K, S159R, Q193H, W193K, N199R, N199R / K201H, N199H / K201R, G131R / N199R / K201H, G131R / N199R / K201H, G131R / N199R / K201H, 1H / R149I / S159R / S215D, G131R / R149I / S159R / S215D, G131R / D218H, K201R, K201H, K204E, K204D, K204L, K204Y, K212R, S215E, S215H, S215K, S215D, D218H, K251D, K251E, K251Q, and Y189Q / R191K / Q193R / H264R / I266L / D267Q.

[0075] In certain embodiments, amino acid substitutions of TRAIL variants are selected based on variants having reduced affinity for TRAIL decoy receptors; such substitutions can be selected from T261L, H270D, T200H, T261L / G160E, T261L / H270D, T261L / G160E / H270D, T261L / G160E / H270D / T200H, D203A and D218A.

[0076] The inventors have previously genetically modified NK cells to express mutated TRAIL. Modified KHYG-1 cells and NK-92 cells express mutated TRAIL. Modified KHYG-1 cells show improved cytotoxicity to cancer cell lines in vitro. These cell lines express TRAIL receptors (such as DR4 and DR5). Other preferred embodiments of modified immune effector cells do not express or substantially do not express TRAIL receptors, or only express at low levels-low enough so that the viability of modified immune effector cells is not adversely affected by the expression of mutated TRAIL. In addition, as described herein, immune effector cells with TRAIL receptors connected to costimulatory domains can be used.

[0077] In an optional embodiment, the treatment of cancer using modified immune effector cells expressing TRAIL or TRAIL variants is enhanced by administering to the patient an agent that can increase the expression of TRAIL death receptors on cancer cells. The agent can be administered before the modified immune effector cells are administered, co-administered with immune effector cells, or administered after the modified immune effector cells are administered. However, it is preferred that the agent be administered before the modified immune effector cells are administered. In a preferred embodiment, the drug increases the expression of DR5 on cancer cells. The agent can optionally be a chemotherapeutic drug, such as bortezomib, and is administered at a low dose that can increase the expression of DR5 on cancer cells. The present invention is not limited to any specific agent that can increase the expression of DR5, but examples of DR5 inducers include bortezomib, gefitinib, Piperlongumine, doxorubicin, alpha-tocopheryl succinate, and HDAC inhibitors.

[0078] Mutant / variant TRAIL ligands may also be linked to one or more immune effector cell co-stimulatory domains, such as 41BB / CD137, CD3zeta / CD247, DAP12 or DAP10. Binding of the variant to its receptor on the target cell thus promotes apoptotic signaling within the target cell and further stimulates cytotoxic signaling in the immune effector cell.

[0079] According to a further preferred embodiment of the present invention, modified immune effector cells are provided which additionally have reduced checkpoint inhibitory receptor function and further express a mutated TRAIL ligand, as described in more detail above with respect to these respective immune effector cell modifications.

[0080] The present invention also provides immune effector cells and immune effector cell lines modified to express one or more CARs, preferably NK-92 cells and their derivatives.

[0081] Suitable for cancer treatment purposes, CAR specifically binds to one or more ligands on cancer cells, such as CS1 (SLAMF7) on myeloma cells. For the treatment of specific cancers, such as multiple myeloma, CAR can bind to CD38. For example, CAR may include, for example, a binding property derived from, similar to, or equivalent to a variable region from a known monoclonal antibody daratumumab. Such immune effector cells can be used in combination with angiogenesis-inhibiting agents, such as lenalidomide, for cancer treatment. For the treatment of cancer, particularly leukemia, especially AML, CAR can be combined with CLL-1.

[0082] CAR-NK cells and CAR-T cells may be bispecific, where they have affinity for two different ligands / antigens. Bispecific CAR can be used to increase the number of potential binding sites on cancer cells, or alternatively, for locating cancer cells to other immune effector cells expressing CAR-specific ligands. For cancer treatment, bispecific CAR can be bound to target tumor cells and bound to effector cells, such as T cells, NK cells or macrophages. Therefore, for example, in the case of multiple myeloma, bispecific CAR can bind to T cell antigens (such as CD3, etc.) and tumor cell markers (such as CD38, etc.). Bispecific CAR can selectively bind to two separate tumor cell markers, thereby increasing the total binding affinity of immune effector cells to target tumor cells. This can reduce the risk of cancer cells developing drug resistance by downregulating one of the target antigens. In this case, an example in multiple myeloma is that CAR is combined with CD38 and CS-1 / SLAMF7. Another tumor cell marker that CAR appropriately targets is a "don't eat me" type marker on the tumor, such as CD47.

[0083] Optional features of the present invention include providing further modifications to the above-mentioned immune effector cells and immune effector cell lines, wherein, for example, Fc receptors (which may be CD16, CD32 or CD64, including subtypes and derivatives) are expressed on the surface of the cells. In use, these cells may exhibit increased recognition of antibody-coated cancer cells and improved activation of cytotoxic responses.

[0084] Further optional features of the present invention include adapting modified immune effector cells and immune effector cell lines to better home to specific target areas of the body. The immune effector cells of the present invention can target specific cancer cell locations. In a preferred embodiment for treating blood cancer, the immune effector cells of the present invention are suitable for homing to the bone marrow. Specific immune effector cells are modified by fucosylation and / or sialylation and home to the bone marrow. This can be achieved by genetically modifying immune effector cells to express suitable fucosyltransferases and / or sialyltransferases, respectively. Increased homing of immune effector cells to tumor sites can also be achieved by destroying tumor vasculature (e.g., by metronomic chemotherapy) or by using drugs targeting angiogenesis (Melero et al., 2014) to normalize the infiltration of immune effector cells via cancer vessels.

[0085] Another optional feature of the present invention is to provide modified immune effector cells and immune effector cell lines with increased intrinsic ability for rapid growth and proliferation in culture. This can be achieved by, for example, transfected cells to express or overexpress one or more growth-inducing cytokines. Examples of suitable cytokines for this purpose include IL-2 and IL-15. In addition, this optional change (alteration) provides a cost-effective alternative method to continuously supplement growth medium with cytokines.

[0086] It is preferred to expand primary NK cells using IL-15, as it has been observed that expansion of primary NK cells in the presence of IL-2 may upregulate DR5 expression, thereby rendering the cells more susceptible to self-killing.

[0087] The present invention also provides a method for preparing a modified immune effector cell or immune effector cell line, comprising genetically modifying the cell or cell line described herein to make it more resistant to TRAIL-induced cell death and / or increase its cytotoxicity. This genetic modification can be, for example, stable knockout of a gene by CRISPR, or transient knockdown of a gene by, for example, siRNA.

[0088] In a preferred embodiment, in order to provide new immune effector cell lines (as described above), such as derivatives of NK-92 cells, with increased resistance to TRAIL-induced cell death and increased cytotoxicity, a stable genetic modification technology, such as CRISPR, is used.

[0089] In embodiments, the methods can also be used to prepare immune effector cells or immune effector cell lines that have been modified to reduce inhibitory receptor function. Preferably, these inhibitory receptors are checkpoint inhibitory receptors.

[0090] More specific embodiments include methods for preparing immune effector cells or immune effector cell lines with reduced inhibitory receptor function, wherein the checkpoint inhibitory receptor is selected from CD96 (TACTILE), CD152 (CTLA4), CD223 (LAG-3), CD279 (PD-1), CD328 (SIGLEC7), SIGLEC9, TIGIT and TIM-3.

[0091] In preferred embodiments, the method comprises modifying immune effector cells to reduce the function of two or more inhibitory receptors.

[0092] The present invention further provides a method for preparing a modified immune effector cell or immune effector cell line, which comprises genetically modifying the cell or cell line to express a TRAIL ligand or a mutated TRAIL (variant) ligand.

[0093] In embodiments, the method comprises modifying an immune effector cell or immune effector cell line to express a mutant TRAIL ligand with increased affinity to a TRAIL receptor. Preferably, the TRAIL receptor is DR4 and / or DR5. A preferred embodiment provides a method of modifying an immune effector cell or immune effector cell line to express a mutant TRAIL ligand with reduced affinity to a decoy TRAIL receptor.

[0094] In a further preferred embodiment, the method comprises modifying the immune effector cell or immune effector cell line to remove the function of the checkpoint inhibitory receptor and also express a mutated TRAIL ligand with reduced or no binding affinity for the decoy TRAIL receptor.

[0095] Further typical embodiments provide methods for preparing immune effector cells or immune effector cell lines, wherein the function of one or more checkpoint inhibitory receptors has been removed and / or a mutant TRAIL ligand is expressed, which has reduced or no binding affinity to the decoy TRAIL receptor, and the cell is further modified to express CAR or bispecific CAR. The characteristics of CAR are optionally as described above.

[0096] In embodiments, the method includes preparing immune effector cells or immune effector cell lines, wherein the function of one or more checkpoint inhibitory receptors has been removed and / or a mutated TRAIL ligand is expressed, which has reduced or no binding affinity to decoy TRAIL receptors, and the cells are optionally modified to express CAR or bispecific CAR, and the cells are further modified to express one or more Fc receptors. Suitable Fc receptors are selected from CD16 (FcRⅢ), CD32 (FcRⅡ) and CD64 (FcRⅠ).

[0097] All of the above preferred embodiments include methods of making NK cells and NK cell lines, and the NK cell lines are derivatives of NK-92.

[0098] According to the purpose of the present invention, modified immune effector cells, immune effector cell lines or compositions thereof with increased cytotoxicity are used to treat cancer in a patient, in particular a blood cancer, in particular a cancer in a human.

[0099] In a preferred embodiment, the modified immune effector cells, immune effector cell lines or compositions are used to treat blood cancers including acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), Hodgkin lymphoma, non-Hodgkin lymphoma including T-cell lymphoma and B-cell lymphoma, asymptomatic myeloma, smoldering multiple myeloma (SMM), active myeloma or light chain myeloma.

[0100] In an even more preferred embodiment, the NK cell line is obtained as a derivative of NK-92 as described in the present invention, optionally additionally modified by reducing checkpoint inhibitory receptor function in NK-92 cells or expressing a mutated TRAIL ligand in NK-92 cells, or by both, for the treatment of blood cancers.

[0101] The modified immune effector cells, immune effector cell lines and compositions thereof described herein are suitable for treating cancer, particularly cancer in humans, for example, for treating blood cell cancer or solid cancer. The immune effector cells and derivatives are preferably human immune effector cells. For human treatment, human immune effector cells are preferably used.

[0102] Various routes of administration are known to those skilled in the art to deliver active agents and compositions thereof to patients in need thereof. Embodiments of the present invention are used for the treatment of blood cancers. Administration of modified immune effector cells and / or immune effector cell lines can be systemic or local, for example, by an intraperitoneal route.

[0103] In other embodiments, the active agent is administered more directly. Thus, administration can be performed directly into the tumor, which is particularly useful for solid tumors.

[0104] It is generally believed that immune effector cells are suitable for the methods, uses and compositions of the present invention. According to the cells used in certain embodiments herein, NK cells / T cells can be NK cells / T cells obtained from cancer cell lines. Advantageously, NK / T cells, preferably treated, for example by causing them to die and / or be unable to divide, to reduce their tumorigenicity, can be obtained from blood cancer cell lines and used in the methods of the present invention for treating blood cancers.

[0105] In order to make cancer-derived cells more acceptable for therapeutic use, they are usually treated or pretreated in some way to reduce or eliminate their tendency to form tumors in patients. Specific modified NK cell lines, such as NK-92 cells are safe because they may become unable to divide; they are irradiated and retain their killing ability, but die in about 3-4 days. Therefore, for example, due to radiation, specific cells and cell lines cannot proliferate. The processing of potential immune effector cells used in the methods herein includes radiation to prevent them from dividing and forming tumors in vivo, and genetic modification to reduce tumorigenicity, such as inserting a sequence encoding a suicide gene (suicide gene) that can be activated to prevent cells from dividing and forming tumors in vivo. Suicide genes can be turned on by exogenous, such as circulating agents, and then cause cell death in cells expressing the gene. Another option is to use monoclonal antibodies of specific immune effector cells of targeted therapy. For example, CD52 is expressed on KHYG-1 cells, and binding of a monoclonal antibody to this marker results in antibody-dependent cell-mediated cytotoxicity (ADCC) and KHYG-1 cell death.

[0106] As discussed in an article published by Suck et al. in 2006, using Irradiators such as the 3000Elan can easily irradiate cancer-derived NK cells and cell lines. Cesium-137 sources are used to control the radiation dose, for example, a dose response curve between 1Gy and 50Gy can be used to determine the optimal dose to eliminate the cell's proliferative capacity while maintaining the benefit of increased cytotoxicity. This is achieved by measuring the cytotoxicity of the cells after each dose of radiation is administered.

[0107] The use of irradiated NK cell lines for adoptive cellular immunotherapy has significant advantages over established autologous or MHC-matched T cell approaches. First, the use of immune effector cell lines with highly proliferative properties means that expansion of modified NK cell lines can be more easily achieved at a commercial level. The modified immune effector cell lines can then be irradiated before the cells are administered to the patient. These irradiated cells retain their useful cytotoxicity, have a limited lifespan, and, unlike modified T cells, do not circulate for long periods of time leading to persistent side effects.

[0108] In addition, the use of allogeneic modified immune effector cells and immune effector cell lines means that MHC class I expressing cells in the patient cannot suppress immune effector cell cytotoxic responses in the same way as they suppress autoimmune effector cell cytotoxic responses. The use of allogeneic immune effector cells and cell lines to kill cancer cells benefits from the aforementioned GVL effect, and unlike autologous T cells, allogeneic immune effector cells and cell lines do not stimulate the occurrence of GVHD, making them a more preferred choice for treating cancer through adoptive cellular immunotherapy.

[0109] Implementation

[0110] According to the present invention, the following embodiments are provided:

[0111] 1. An immune effector cell or immune effector cell line which has been modified to have increased resistance to TRAIL-induced cell death.

[0112] 2. The immune effector cell or immune effector cell line according to embodiment 1, wherein the immune effector cell is a NK cell.

[0113] 3. The immune effector cell or immune effector cell line according to embodiment 1, wherein the immune effector cell is a T cell.

[0114] 4. The immune effector cell or immune effector cell line according to any preceding embodiment, wherein the resistance to TRAIL-induced cell death is increased by at least 10% relative to wild-type immune effector cells.

[0115] 5. An immune effector cell or immune effector cell line according to any preceding embodiment, which is modified to knock down or knock out the expression of one or more TRAIL receptor genes.

[0116] 6. An immune effector cell or immune effector cell line according to any preceding embodiment, which expresses or is modified to express a TRAIL receptor linked to a co-stimulatory domain.

[0117] 7. The immune effector cell or immune effector cell line according to embodiment 5 or 6, wherein the TRAIL receptor is selected from DR4 and DR5.

[0118] 8. An immune effector cell or immune effector cell line according to embodiment 6 or 7, wherein the co-stimulatory domain is selected from 4-1BB, CD28, 2B4, DAP-10, DAP-12, CD278 (ICOS) and OX40.

[0119] 9. The immune effector cell or immune effector cell line according to any preceding embodiment, further expressing or modified to express a mutated TRAIL ligand.

[0120] 10. The immune effector cell or immune effector cell line of embodiment 9, wherein the mutated TRAIL ligand has an increased affinity for a TRAIL receptor, e.g., DR4 and / or DR5.

[0121] 11. The immune effector cell or immune effector cell line according to any preceding embodiment, wherein the cell line is NK-92 or KHYG-1 or a derivative thereof.

[0122] 12. An immune effector cell or immune effector cell line according to any preceding embodiment for use in treating cancer in a patient.

[0123] 13. An immune effector cell or immune effector cell line for use according to embodiment 12, wherein the cancer is a blood cancer.

[0124] 14. An immune effector cell or immune effector cell line for use according to embodiment 13, wherein the blood cancer is acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), Hodgkin's lymphoma, non-Hodgkin's lymphoma including T-cell lymphoma and B-cell lymphoma, asymptomatic myeloma, smoldering multiple myeloma (SMM), active myeloma or light chain myeloma.

[0125] 15. A NK-92 cell or a KHYG-1 cell modified to express a TRAIL receptor linked to a co-stimulatory domain.

[0126] 16. The NK-92 cell or KHYG-1 cell according to embodiment 15, wherein the TRAIL receptor is selected from DR4 and DR5.

[0127] 17. The NK-92 cell or KHYG-1 cell according to embodiment 15 or 16, wherein the co-stimulatory domain is selected from 4-1BB, CD28, 2B4, DAP-10, DAP-12, CD278 (ICOS) and OX40.

[0128] The present invention will now be described in terms of specific embodiments with reference to the accompanying drawings, in which:

[0129] Figure 1 It was shown that knocking down DR5 expression alleviates NK cell self-killing;

[0130] Figure 2 The expression of DR5 on T cells is shown;

[0131] Figure 3 Transfection of T cells with DR5-41BB chimera is shown;

[0132] Figure 4 It was shown that TRAIL-induced T cell death was alleviated by expression of DR5-41BB chimera;

[0133] Figure 5 The expression of DR5 on NK cells is shown;

[0134] Figure 6 Transfection of NK cells with DR5-41BB chimera is shown.

[0135] The DNA, RNA and amino acid sequences are given below, where:

[0136] SEQ ID NO: 1 is an example of a gRNA for DR5;

[0137] SEQ ID NO: 2 is an example of a gRNA for DR4;

[0138] SEQ ID NO: 3 is a second example of a gRNA for DR4;

[0139] SEQ ID NO: 4 is the DR5-41BB chimera DNA sequence. Example

[0140] The present invention is now described in greater and more specific detail regarding the preparation of immune effector cells modified to exhibit reduced sensitivity to TRAIL-induced cell death and / or enhanced cytotoxic activity and thus increased ability to cause cancer cell death in humans.

[0141] For related examples of knockout / knockdown of checkpoint inhibitory receptor function and knockin of mutant TRAIL, see WO 2017 / 017184.

[0142] Example 1 Knockout of NK cell TRAIL receptors DR4 and DR5

[0143] NK cells in which the functions of death receptor 5 (DR5) and / or death receptor 4 (DR4) were eliminated were prepared as follows.

[0144] Designed and prepared gRNA constructs targeting TRAIL-R2 (DR5) and TRAIL-R1 (DR4) (e.g., SEQ ID NO: 1: CCCAUCUUGAACAUACCAG (DR5), SEQ ID NO: 2: AACCGGUGCACAGAGGGUGU (DR4) and SEQ ID NO: 3: AUUUACAAGCUGUACAUGGG (DR4)) to target endogenous genes encoding DR5 and DR4 genes in NK cells. CRISPR / Cas9 genome editing was then used to knock out the DR5 target gene and / or DR4 target gene.

[0145] A total of 3 candidate gRNAs were selected for the DR5 gene, and their cleavage efficacy was determined in RPMI8226 cells. A total of 3 candidate gRNA genes were selected for the DR4 gene, and their cleavage efficacy was determined in HL60 cells. GT electroporated RPMI8226 cells and HL60 with gRNA:Cas9 ribonucleoprotein (RNP) complexes, followed by knockout of DR5 and / or analysis by flow cytometry. The cleavage activity of gRNA was also measured using an in vitro mismatch detection assay. T7E1 endonuclease recognizes and cleaves non-perfectly matched DNA, allowing comparison of the parental DR5 gene / DR4 gene with the mutant gene after CRISPR / Cas9 transfection and non-homologous end joining (NHEJ).

[0146] The gRNA with the highest KO efficiency was selected for further experiments to knock out DR5 / DR4 in primary NK cells, NK cell lines or CD34+ progenitor cells (for subsequent differentiation and expansion into NK cells). Knockout of DR4 / DR5 was determined by flow cytometry-based analysis.

[0147] Example 2 Knockdown of TRAIL receptors DR4 and DR5 in NK cells

[0148] siRNA knockdown of DR4 and / or DR5 in NK-92 cells, KHYG-1 cells, and primary NK cells by electroporation. Nucleofection Kit T can be used with Amaxa Nucleofection Reagent II purchased from Lonza because it is suitable for NK cells and can successfully transfect both dividing and non-dividing cells with up to 90% transfection efficiency.

[0149] Warm Nucleofector solution to room temperature (100ul per sample). Also pre-warm a portion of medium containing serum and supplements at 37°C in a 50ml tube. Prepare a 6-well plate by adding 4ml of medium containing serum and supplements. Pre-incubate the plate in a humidified 37°C / 5% CO2 incubator.

[0150] In 100 μl of nucleofection solution, 2 × 10 6 Gently mix the cells with the 20 μM siRNA solution to achieve a final concentration of 2 μM. Avoid bubbles during mixing. Transfer the mixture to an Amaxa certified cuvette and place it in the Nucleofector cuvette holder.

[0151] Allow the program to run and complete, and immediately remove the samples from the cuvettes. Then add 500 μl of pre-equilibrated culture medium to each cuvette. Then, gently pipette the sample from each cuvette into the corresponding well of the prepared 6-well plate to establish a final volume of 5 ml per well.

[0152] The cells were then cultured in a humidified 37°C / 5% CO2 incubator until transfection analysis. Flow cytometry analysis was performed 72 hours after electroporation to measure the expression levels of DR4 and / or DR5. This electroporation protocol was found to reliably result in knockout of DR4 and DR5 in KHYG-1 cells, NK-92 cells, and primary NK cells.

[0153] Example 3 DR4-CD28 / DR5-CD28 fusion protein

[0154] The immunomodulatory fusion protein (IFP) may comprise the extracellular domain of DR4 or DR5 or a portion thereof, and the intracellular signaling domain of CD28 or a portion thereof. The hydrophobic component may consist of the transmembrane domain of DR4 / DR5 or the transmembrane domain of CD28 or a portion thereof. In some DR4-CD28 or DR5-CD28 fusion proteins, the hydrophobic component comprises the transmembrane domain of CD28, and the extracellular component further comprises the extracellular portion of CD28, particularly the extracellular cysteine ​​residues adjacent to the hydrophobic component. The extracellular component may comprise the entire extracellular domain or a portion of the extracellular domain of DR4 or DR5.

[0155] The extracellular component may include the entire extracellular domain of DR4 / DR5. Thus, the DR4-CD28 or DR5-CD28 construct has the ability to convert the inhibitory signal normally coming from DR4 or DR5 bound to TRAIL into a positive signal generated by the intracellular signaling domain of CD28.

[0156] Exemplary nucleic acid molecules encoding DR4-CD28 fusion proteins or DR5-CD28 fusion proteins comprise the following elements (5' to 3'): extracellular component (DR4 / DR5) - multimerization domain (CD28 cysteine) - hydrophobic component (CD28 transmembrane) - intracellular component (CD28 intracellular).

[0157] Nucleic acid encoding the construct can be generated in-house by PCR and then TOPO cloned into pENTR TM / vector (Invitrogen) and used Technology (Invitrogen) was transferred into the retroviral vector pMP71-attR. In some cases, the nucleic acid molecule encoding IFP was codon optimized before being cloned into the pMP71-attR retroviral vector.

[0158] Example 4 Knock-in of modified TRAIL receptor in NK cells

[0159] NK-92 cells, KHYG-1 cells and primary expanded NK cells were transfected with genes encoding DR5 or DR4 linked to the co-stimulatory domains CD28 (as above) or 4-1BB.

[0160] A group of genes encoding immunomodulatory fusion proteins (IFPs) were generated, which contain DR5 or DR4 extracellular binding domains fused to 4-1BB or CD28 costimulatory domains rather than natural death domains. Specifically, the selected gene can encode an IFP containing a DR5 backbone and a transmembrane and stem region of CD8a containing 4-1BB or CD28 and CD3zeta endodomains. Gene constructs are delivered in the form of mRNA for transient expression, and stable long-term expression is established using SB vectors.

[0161] After transfection of NK cells with IFP (using Nucleofection Kit T as described above), successfully transfected cells were selected based on their IFP function. The selected cells were then cultured and passaged as described above.

[0162] The resulting IFP expressed in NK cells competes with wild-type DR5 for binding to TRAIL, but unlike wild-type DR5, IFP generates an activation signal upon binding, resulting in a more cytotoxic NK cell phenotype.

[0163] Example 5 Increased resistance of modified NK cells to TRAIL-induced killing

[0164] Wild-type NK cells were compared with the genetically modified NK cells of Example 1, Example 2, Example 3 and Example 4.

[0165] Experimental design 1:

[0166] The sensitivity of each cell type to TRAIL-induced cell death when co-cultured with RPMI-8226, MM1S, HL60, Panc-1, and BxPC3 was assessed by flow cytometry. Briefly, for each cancer target cell type, (1) wild-type NK cells, (2) cells expressing the high affinity membrane-bound TRAIL ligand DR4 4C9 or DR5 E195R;D269H NK cells, (3) with DR4 KO or DR5 KO NK cells, and (4) expressing the high affinity membrane-bound TRAIL ligand DR4 4C9 or DR5 E195R;D269H of NK cells.

[0167] Experimental design 2:

[0168] The sensitivity of each cell type to TRAIL-induced cell death when co-cultured with RPMI-8226, MM1S, HL60, Panc-1, and BxPC3 was assessed by flow cytometry. Briefly, for each cancer target cell type, (1) wild-type NK cells, (2) cells expressing the high affinity membrane-bound TRAIL ligand DR4 4C9 or DR5 E195R;D269H NK cells, (3) with DR4 KI-IFP or DR5 KI-IFP NK cells, and (4) NK cells with DR4 KI-IF P or DR5 KI-IFP and expresses the high affinity membrane-bound TRAIL ligand DR4 4C9 or DR5 E195R;D269H of NK cells.

[0169] Experimental design three:

[0170] The sensitivity of each cell type to TRAIL-induced cell death when co-cultured with RPMI-8226, MM1S, HL60, Panc-1, and BxPC3 was assessed by flow cytometry. Briefly, for each cancer target cell type, (1) wild-type NK cells, (2) cells expressing the high affinity membrane-bound TRAIL ligand DR4 4C9 or DR5 E195R;D269H NK cells, (3) with DR4 KO or DR5 KO NK cells, (4) with DR4 KI-IFP or DR5 KI-IFP NK cells, (5) NK cells and DR4 KO With DR4 KI-IFP or DR5 KO With DR5 KI-IFP and expresses the high affinity membrane-bound TRAIL ligand DR4 4C9 or DR5 E195R;D269H of NK cells.

[0171] Example 6 Knockout of T cell TRAIL receptor DR4 and receptor DR5

[0172] T cells in which the function of death receptor 5 (DR5) and / or death receptor 4 (DR4) was eliminated were prepared as follows.

[0173] Designed and prepared targeting TRAIL-R2 (DR5) and TRAIL-R1 (DR4) gRNA constructs (e.g., SEQ ID NO: 1: CCCAUCUUGAACAUACCAG (DR5), SEQ ID NO: 2: AACCGGUGCACAGAGGGUGU (DR4) and SEQ ID NO: 3: AUUUACAAGCUGUACAUGGG (DR4)) to target endogenous genes encoding DR5 and DR4 genes in T cells. CRISPR / Cas9 genome editing was then used to knock out the DR5 target gene and / or DR4 target gene.

[0174] A total of 3 candidate gRNAs were selected for the DR5 gene, and their cleavage efficiency was determined in RPMI8226 cells. A total of 3 candidate gRNAs were selected for the DR4 gene, and their cleavage efficiency was determined in HL60 cells. GT RPMI8226 cells and HL60 were electroporated with gRNA:Cas9 ribonucleoprotein (RNP) complexes and subsequently DR5 knockout and / or analyzed by flow cytometry. The cleavage activity of gRNA was also determined using an in vitro mismatch detection assay. T7E1 endonuclease recognizes and cleaves non-perfectly matched DNA, allowing comparison of the parental DR5 gene / DR4 gene with the mutant gene after CRISPR / Cas9 transfection and non-homologous end joining (NHEJ).

[0175] The gRNA with the highest KO efficiency was selected for further experiments to knock out DR5 / DR4 in primary T cells, T cell lines or progenitor cells (for subsequent differentiation and expansion into T cells). Knockout of DR4 / DR5 was determined by flow cytometry-based analysis.

[0176] Example 7 Resistance to NK Cell Self-killing

[0177] like Figure 1 As shown, NK cell autokilling was evaluated in the following cells: (1) primary NK cells, also called mock or wild-type NK cells, and (2) cells expressing the high-affinity membrane-bound TRAIL ligand DR5. E195R;D269H Primary NK cells, (3) siRNA with DR5 KD primary NK cells, and (4) siRNA with DR5 KD And also express the high affinity membrane-bound TRAIL ligand DR5 E195R;D269H of primary NK cells.

[0178] Primary NK cells undergoing DR5 knockdown were electroporated with DR5 siRNA on day 9 of expansion, whereas primary NK cells undergoing DR5 TRAIL variants were electroporated with variant mRNA on day 12 of expansion.

[0179] It was observed that DR5 expression was upregulated following prolonged expansion of primary NK cells in growth medium containing IL-2, leading to increased self-killing when expressing DR5 TRAIL variants.

[0180] The data clearly demonstrate that knocking down DR5 expression using siRNA protects primary expanded NK cells from self-killing, regardless of whether these NK cells express wild-type TRAIL or the high-affinity DR5 TRAIL variant.

[0181] Example 8 DR5 expression on T cells

[0182] The expression of TRAIL death receptor 5 (DR5) was detected on Jurkat T cells.

[0183] Jurkat T cells were cultured in the presence of RPMI-1640, 10% FBS and 1% penicillin-streptomycin. Cells were harvested in the logarithmic growth phase and immunophenotypic analysis of cell surface expression of TRAIL-DR5 / CD262 was performed according to standard protocols.

[0184] Briefly, the cells were washed with a buffer containing PBS, sodium azide and 2% FBS. Subsequently, the cells were resuspended in an appropriate volume and stained with anti-DR5 antibody (clone: ​​DJR2-4, source: Biolegend, product number: 307406). The cells were then incubated with 2 μl of the antibody for 20 minutes on ice. After incubation, the cells were washed twice with a buffer containing PBS, sodium azide and 2% FBS to remove unbound antibodies. Finally, the cells were resuspended in 200 μl of buffer containing PBS, sodium azide and 2% FBS and measured by a BD FACS CantoⅡ flow cytometer using a 488 nm blue laser and a 585 / 42 bandpass filter to detect the emitted signal. The results were analyzed using FlowJo software (version X).

[0185] Figure 2 The expression of DR5 on Jurkat T cells in both the FMO control sample (1.29%) and the anti-DR5 stained sample (86.8%) is shown.

[0186] It is evident that Jurkat T cells highly express the TRAIL death receptor 5 (DR5) on their surface.

[0187] Example 9 Expression of DR5-41BB chimera on T cells

[0188] The DR5-41BB fusion protein (SEQ ID NO: 4) was expressed in Jurkat T cells to convert the DR5 apoptotic signaling cascade into an active, stimulatory T cell response.

[0189] Jurkat T cells were cultured in the presence of RPMI-1640, 10% FBS, and 1% penicillin-streptomycin. Cells were harvested during the logarithmic growth phase and transfected using mRNA electroporation under a standard electroporation protocol. DR5-41BB mRNA was used at a concentration of 1 μg / μl in citrate buffer. Cells were washed once in buffer solution and then incubated at 2 × 10 6 The cells were concentrated at a density of 10 cells / 100 μl. The cells were blank electroporated or electroporated with a DR5-41BB chimera at a final concentration of 10 μg / 100 μl. After electroporation, the cells were immediately recovered in a 6-well plate and recovered at 37 ° C for 20 minutes. After incubation, the cells were supplemented with a culture medium containing RPMI-1640 and 10% FBS. Before analyzing the expression of DR5-41BB chimeras by flow cytometry, the cells were revived and incubated again at 37 ° C for 24 hours.

[0190] Briefly, cells were washed with a buffer containing PBS, sodium azide, and 2% FBS. Subsequently, cells were resuspended in an appropriate volume and stained with anti-DR5 antibody (clone: ​​DJR2-4, source: Biolegend, product number: 307406). The cells were then incubated with 2 μl of antibody for 20 minutes on ice. After incubation, cells were washed twice with a buffer containing PBS, sodium azide, and 2% FBS to remove unbound antibodies. Finally, cells were resuspended in 500 μl of buffer containing PBS, sodium azide, and 2% FBS and measured by a BD FACS CantoⅡ flow cytometer using a 488 nm blue laser and a 585 / 42 bandpass filter to detect the emitted signal. The results were analyzed using FlowJo version X.

[0191] Figure 3The expression of DR5-41BB chimera on Jurkat T cells is shown. The expression of DR5 in blank (mock) electroporated Jurkat T cells showed an average MFI (mean fluorescence intensity) value of 698. The expression of DR5 and DR5-41BB on transfected Jurkat T cells showed an average MFI value of 2073. When the blank electroporated (mockelectroporated) T cells were normalized to the background MFI=0, it can be seen that the DR5-41BB specific expression is equal to the average MFI value of 1375.

[0192] Therefore, it was shown that the DR5-41BB chimera could be successfully expressed in T cells.

[0193] Example 10 Protective Effect of DR5-41BB Chimera

[0194] The vulnerability of wild-type Jurkat T cells and Jurkat T cells expressing the DR5-41BB chimera from Example 9 was assessed when exposed to TRAIL ligand.

[0195] Jurkat T cells were cultured in the presence of RPMI-1640, 10% fetal bovine serum, and 1% penicillin-streptomycin. Cells were harvested during the logarithmic growth phase and transfected using mRNA electroporation under a standard electroporation protocol. DR5-41BB mRNA was used at a concentration of 1 μg / μl in citrate buffer. Cells were washed once in buffer solution and then incubated at 2 × 10 6 The cells were concentrated to a density of 10 cells / 100 μl. The cells were mock electroporated or electroporated with DR5-41BB chimera at a final concentration of 10 μg / 100 μl. After electroporation, the cells were immediately recovered in a 6-well plate and revived at 37°C for 20 minutes. After incubation, the cells were supplemented with medium containing RPMI-1640 and 10% FBS.

[0196] Cells were allowed to recover and cultured for an additional 4 hours at 37°C before being used in a functional assay in 96-well plates to assess the toxicity of TRAIL ligands on Jurkat T cells electroporated with (a) mock or (b) DR5-41BB mRNA.

[0197] like Figure 4As shown, T cells were cultured in the presence or absence of a final concentration of 100 ng / ml of soluble TRAIL ligand. Each plot represents n=3. The assay was continued for 16 hours, and cell death in T cells was assessed by propidium iodide using a flow cytometer on a BD FACS CantoⅡ-based analysis platform. Although the presence of TRAIL ligands clearly had a toxic effect on T cells (about 37.5% cell death), this TRAIL-induced cell death could be circumvented by expressing the DR5-41BB chimeric receptor (about 15% cell death).

[0198] Thus, it was shown that expression of the DR5-41BB chimera confers resistance to TRAIL-induced cell death to T cells.

[0199] Example 11 Expression of DR5-41BB chimera on NK cells

[0200] The DR5-41BB fusion protein (SEQ ID NO: 4) was expressed in primary expanded NK cells to convert the DR5 apoptotic signaling cascade into an activated, activated NK cell response.

[0201] Primary expanded NK cells were cultured for 12 days in the presence of 10% human AB serum in Miltenyi Biotec cell expansion medium according to the manufacturer's guidelines. Cells were harvested during the logarithmic growth phase and transfected using mRNA electroporation under a standard electroporation protocol. DR5-41BB mRNA was used at a concentration of 1 μg / μl in citrate buffer. Cells were washed once in buffer and then incubated at 2 × 10 6 Cells were either electroporated or electroporated with DR5-41BB chimera at a final concentration of 7.5 μg / 100 μl.

[0202] After electroporation, cells were immediately recovered in 6-well plates and revived at 37°C for 20 minutes. After incubation, cells were supplemented with NK cell MACS medium (Miltenyi Bioctec) containing 10% human AB serum. Cells were allowed to recover and incubated again at 37°C for 24 hours before analysis of the expression of DR5-41BB chimeras by flow cytometry.

[0203] Briefly, cells were washed with a buffer containing PBS, sodium azide, and 2% FBS. Subsequently, cells were resuspended in an appropriate volume and stained with anti-DR5 antibody (clone: ​​DJR2-4, source: Biolegend, product number: 307406). The cells were then incubated with 2 μl of the antibody for 20 minutes on ice. After incubation, cells were washed twice with a buffer containing PBS, sodium azide, and 2% FBS to remove unbound antibodies. Finally, cells were resuspended in 500 μl of buffer containing PBS, sodium azide, and 2% FBS and measured by a BD FACS CantoⅡ flow cytometer using a 488 nm blue laser and a 585 / 42 bandpass filter to detect the emitted signal. The results were analyzed using FlowJo version X.

[0204] Figure 5 Figure 4 shows the expression of DR5 receptor in blank electroporated NK cells (average MFI value: 208), while Figure 6 DR5 receptor expression in DR5-41BB chimeric mRNA electroporated NK cells is shown (average MFI value: 608). When blank electroporated NK cells are normalized to background MFI=0, it can be seen that DR5-41BB specific expression (608 minus 208) is equal to 400 MFI units.

[0205] Therefore, it was shown that DR5-41BB fusion protein could be successfully expressed in NK cells and T cells.

[0206] Therefore, the present invention provides immune effector cells and cell lines resistant to TRAIL-induced cell death, and their preparation, for the purposes of cancer treatment. This method relates to a combination of knocking down / knockout TRAIL receptors on immune effector cells to prevent the self-killing of adjacent genetically modified immune effector cells expressing high-affinity membrane-bound TRAIL ligands. In addition, the knock-in of the TRAIL receptor connected to the costimulatory domain allows immune effector cells to convert the self-killing induction signal from the adjacent immune effector cells into the activation signal transduction required for efficient immune effector cell cytotoxicity. <110> ONK Therapeutics Limited <120> Modified immune effector cells with increased resistance to cell death <130> KHP212111292.1 <160> 4 <170> PatentIn version 3.5 <210> 1 <211> 19 <212> RNA <213> Homo sapiens <400> 1 cccaucuuga acauaccag 19 <210> 2 <211> 20 <212> RNA <213> Homo sapiens <400> 2 aaccggugca cagagggugu 20 <210> 3 <211> 20 <212> RNA <213> Homo sapiens <400> 3 auuuacaagc uguacauggg 20 <210> 4 <211> 840 <212> DNA <213> Homo sapiens <400> 4 atggaacaac ggggacagaa cgccccggcc gcttcggggg cccggaaaag gcacggccca 60 ggacccaggg aggcgcgggg agccaggcct gggctccggg tccccaagac ccttgtgctc 120 gttgtcgccg cggtcctgct gttggtctca gctgagtctg ctctgatcac ccaacaagac 180 ctagctcccc agcagagagt ggccccacaa caaaagaggt ccagcccctc agagggattg 240 tgtccacctg gacaccatat ctcagaagac ggtagagatt gcatctcctg caaatatgga 300 caggactata gcactcactg gaatgacctc cttttctgct tgcgctgcac caggtgtgat 360 tcaggtgaag tggagctaag tccctgcacc acgaccagaa acacagtgtg tcagtgcgaa 420 gaaggcacct tccgggaaga agattctcct gagatgtgcc ggaagtgccg cacagggtgt 480 cccagaggga tggtcaaggt cggtgattgt acaccctgga gtgacatcga atgtgtccac 540 aaagaatcag gcatcatcat aggagtcaca gttgcagccg tagtcttgat tgtggctgtg 600 tttgtttgca agtctttact gtggaagaaa atcatctcct tctttcttgc gctgacgtcg 660 actgcgttgc tcttcctgct gttcttctc acgctccgtt tctctgttgt taaacggggc 720 agaagaaac tcctgtatat attcaaacaa ccatttatga gaccagtaca aactactcaa 780 gaggaagatg gctgtagctg ccgatttcca gaagaagaag aaggaggatt tgaactgtga 840

Claims

1. A NK cell or NK cell line which has been modified to have increased resistance to TRAIL-induced cell death, wherein the NK cell or NK cell line is characterized in that: The modification is knocking down or knocking out the expression of TRAIL receptor gene DR4 and / or DR5.

2. The NK cell or NK cell line according to claim 1, wherein the cell line is NK-92 or KHYG-1.

3. Use of the NK cell or NK cell line according to claim 1 or 2 in the preparation of a medicament for treating cancer in a patient, wherein the cancer is leukemia, myeloma or pancreatic cancer.

4. A composition comprising the NK cell or NK cell line according to claim 1 or 2.

5. A method for preparing a modified NK cell or NK cell line, the method comprising modifying the cell to have increased resistance to TRAIL-induced cell death, the method being characterized in that: The modification is knocking down or knocking out the expression of TRAIL receptor gene DR4 and / or DR5. The method according to claim 5 , wherein the cell line is NK-92 or KHYG-1.

Citation Information

Patent Citations

  • Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)

    EP1621550A1

  • Genetically modified human natural killer cell lines

    WO2006023148A2

  • Trail variants for treating cancer

    WO2009077857A2

  • Modified natural killer cells and natural killer cell lines having increased cytotoxicity

    WO2017017184A1

  • Modified natural killer cells and natural killer cell lines having increased cytotoxicity

    CA2993796A1